Equities analysts expect Cambrex Co. (NYSE:CBM) to post sales of $163.21 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cambrex’s earnings. The lowest sales estimate is $161.79 million and the highest is $164.91 million. Cambrex posted sales of $152.05 million during the same quarter last year, which suggests a positive year over year growth rate of 7.3%. The firm is expected to report its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Cambrex will report full-year sales of $645.25 million for the current year, with estimates ranging from $641.75 million to $647.38 million. For the next fiscal year, analysts forecast that the firm will post sales of $659.09 million, with estimates ranging from $656.71 million to $662.96 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Cambrex.
Cambrex (NYSE:CBM) last released its earnings results on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. The company had revenue of $159.46 million for the quarter, compared to analyst estimates of $159.71 million. Cambrex had a net margin of 14.35% and a return on equity of 12.25%. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.72 EPS.
A number of research analysts have issued reports on the stock. Robert W. Baird lowered shares of Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 target price on the stock. in a report on Friday, May 3rd. They noted that the move was a valuation call. ValuEngine upgraded shares of ZIX from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 4th. First Analysis lowered shares of Cambrex from a “strong-buy” rating to an “outperform” rating and upped their target price for the company from $45.00 to $55.00 in a report on Tuesday, May 7th. Finally, Zacks Investment Research upgraded shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $47.80.
NYSE:CBM traded down $1.74 on Friday, reaching $44.13. The stock had a trading volume of 438,045 shares, compared to its average volume of 176,911. The stock has a market cap of $1.49 billion, a P/E ratio of 15.93, a price-to-earnings-growth ratio of 3.58 and a beta of 2.35. The company has a current ratio of 2.96, a quick ratio of 2.01 and a debt-to-equity ratio of 0.79. The stock’s fifty day simple moving average is $43.66. Cambrex has a 12-month low of $33.80 and a 12-month high of $69.43.
Several hedge funds have recently made changes to their positions in CBM. Federated Investors Inc. PA purchased a new position in shares of Cambrex during the 1st quarter worth about $15,991,000. Norges Bank purchased a new position in shares of Cambrex during the 4th quarter worth about $12,632,000. Granite Investment Partners LLC lifted its holdings in shares of Cambrex by 54.5% during the 1st quarter. Granite Investment Partners LLC now owns 445,764 shares of the biotechnology company’s stock worth $17,318,000 after acquiring an additional 157,298 shares during the period. BlackRock Inc. lifted its holdings in shares of Cambrex by 3.2% during the 4th quarter. BlackRock Inc. now owns 4,885,273 shares of the biotechnology company’s stock worth $184,469,000 after acquiring an additional 153,664 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Cambrex by 10.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,654,842 shares of the biotechnology company’s stock worth $62,487,000 after acquiring an additional 153,406 shares during the period.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.